TY - JOUR
T1 - Open-label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch
AU - Williams, Jill M.
AU - Gandhi, Kunal K.
AU - Karavidas, Maria Katsamanis
AU - Steinberg, Marc L.
AU - Lu, Shou En
AU - Foulds, Jonathan
N1 - Funding Information:
This work was supported by grants from the National Institute on Drug Abuse (K23-DA140090-01 to JMW and K23-DA 018203-02 to MLS) and Pfizer, Inc, who also supplied product support. The authors (JMW, JF, MLS) are also supported in part by grants from the New Jersey Department of Health and Senior Services through funds from New Jersey’s Comprehensive Tobacco Control Program.
PY - 2008/10/16
Y1 - 2008/10/16
N2 - Rationale: Nicotine nasal spray (NNS) may be better for relieving acute cigarette cravings than other nicotine replacement and it may help smokers with schizophrenia because of its rapid onset of action. Objectives: We tested whether NNS was more effective than a nicotine patch (NP; 21 mg) in reducing cue-induced craving during a 3-day abstinence. Methods: Twenty-five smokers with schizophrenia or schizoaffective disorder (SA) were randomized to open-label NNS or NP treatment after baseline measures of craving were assessed. NNS users were instructed to dose at a minimum of 1/hour and up to a maximum of 40/day. Averages from a 4-item visual analogue scale (need, urge, want to smoke, crave a cigarette) measured craving. Results: Five subjects who smoked (4 NP, 1 NNS) were excluded, leaving 21 (11 NP, 10 NNS) for analyses. No differences were detected between groups on baseline craving. On day 3, NNS users reported significantly less craving in response to smoking cues compared to NP users (mean craving scores: NNS, 7.0; NP, 20.3; p =.014). A repeated measure ANCOVA demonstrated significantly reduced craving in the NNS group compared to the NP group from baseline to day 3 (F = 5.09; p =.037). NNS users took an average of 20 doses/day, and NNS was rated as being as easy to use as NP. Conclusions: The potential utility of NNS in smokers with schizophrenia supports the need for placebo-controlled studies. 2008 by The Haworth Press. All rights reserved.
AB - Rationale: Nicotine nasal spray (NNS) may be better for relieving acute cigarette cravings than other nicotine replacement and it may help smokers with schizophrenia because of its rapid onset of action. Objectives: We tested whether NNS was more effective than a nicotine patch (NP; 21 mg) in reducing cue-induced craving during a 3-day abstinence. Methods: Twenty-five smokers with schizophrenia or schizoaffective disorder (SA) were randomized to open-label NNS or NP treatment after baseline measures of craving were assessed. NNS users were instructed to dose at a minimum of 1/hour and up to a maximum of 40/day. Averages from a 4-item visual analogue scale (need, urge, want to smoke, crave a cigarette) measured craving. Results: Five subjects who smoked (4 NP, 1 NNS) were excluded, leaving 21 (11 NP, 10 NNS) for analyses. No differences were detected between groups on baseline craving. On day 3, NNS users reported significantly less craving in response to smoking cues compared to NP users (mean craving scores: NNS, 7.0; NP, 20.3; p =.014). A repeated measure ANCOVA demonstrated significantly reduced craving in the NNS group compared to the NP group from baseline to day 3 (F = 5.09; p =.037). NNS users took an average of 20 doses/day, and NNS was rated as being as easy to use as NP. Conclusions: The potential utility of NNS in smokers with schizophrenia supports the need for placebo-controlled studies. 2008 by The Haworth Press. All rights reserved.
UR - https://www.scopus.com/pages/publications/71049165621
UR - https://www.scopus.com/inward/citedby.url?scp=71049165621&partnerID=8YFLogxK
U2 - 10.1080/15504260802085919
DO - 10.1080/15504260802085919
M3 - Article
C2 - 19763279
AN - SCOPUS:71049165621
SN - 1550-4263
VL - 4
SP - 355
EP - 376
JO - Journal of Dual Diagnosis
JF - Journal of Dual Diagnosis
IS - 4
ER -